Editorial Note: This article is written with editorial review and topic relevance in mind.
The convert trial 1 provides early data supporting the omission of radiotherapy for select patients and adds to the myriad options available to patients with rectal cancer. The prospect trial compares folfox chemotherapy with selective use of 5fucrt (intervention) to 5fucrt (control) for neoadjuvant treatment prior to tme for larc. To compare neoadjuvant chemotherapy (nct) with capox alone versus neoadjuvant chemoradiotherapy (ncrt) with capecitabine in locally advanced rectal.
Ten American tourists die mysteriously in the Dominican Republic Fox
Combined chemoradiation therapy is currently the standard practice for locally advanced rectal cancer (larc) with uninvolved mesorectal fascia (mrf). To compare neoadjuvant chemotherapy (nct) with capox alone versus neoadjuvant chemoradiotherapy (ncrt) with capecitabine in locally advanced rectal cancer. We conducted a multicenter, unblinded, noninferiority, randomized trial of neoadjuvant folfox (with chemoradiotherapy given only if the primary tumor decreased in.
Comparatively, nct alone seems a promising alternative.
